Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model

Journal of Korean Medical Science

Volumn 22, Issue 5, 2007, Pages 802-809

  Young, Joon Hong ^a   Myung, Ho Jeong ^a   Sang, Rok Lee ^a   Seo, Na Hong ^a   Kye, Hun Kim ^a   Hyung, Wook Park ^a   Ju, Han Kim ^a   Kim, Weon ^a   Ahn, Youngkeun ^a   Jeong, Gwan Cho ^a   Jong, Chun Park ^a   Jung, Chaee Kang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Blood platelets; Inflammation; Stents

Indexed keywords

EID: 36148944294     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.5.802     Document Type: Article

References (42)

1. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994; 90: 908-14.
2. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994; 331: 1037-43.
3. Kent KM, Bentivoglio LG, Block PC, Bourassa MG, Cowley MJ, Dorros G, Detre KM, Gosselin AJ, Gruentzig AR, Kelsey SF. Longterm efficacy of percutaneous transluminal coronary angioplasty (PTCA): report from the National Heart, Lung, and Blood Institute PTCA Registry. Am J Cardiol 1984; 53: 27-31.
4. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-69.
5. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369-75.
6. Bae Y, Jeong MH, Ahn YK, Park JH, Cho JG, Park JC, Kang JC, Park OK. Comparison of porcine coronary stent restenosis between MAC (Maximal Arterial Re-Creation) stent and Palmaz-Schatz stent. Korean Circ J 1998; 28: 89-96.
7. Giraldo AA, Esposo OM, Meis JM. Intimal hyperplasia as a cause of restenosis after percutaneous transluminal coronary angioplasty. Arch Pathol Lab Med 1985; 109: 173-5.
8. Ahn YK, Jeong MH, Kim JW, Kim SH, Cho JH, Cho JG, Park CS, Juhng SW, Park JC, Kang JC. Preventive effects of the heparincoated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999; 48: 324-30.
9. Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 2005; 69: 1477-83.
10. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-30.
11. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000; 35: 157-63.
12. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
13. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183-8.
14. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-93.
15. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R. Long-term effects of polymerbased, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004; 63: 617-24.
16. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-95.
17. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000; 36: 2325-32.
18. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-9.
19. EPIC (Evaluation of 7E3 in Preventing Ischemic Complications) Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
20. EPILOG (Evaluation in PTCA to improve Long-Term outcome GP IIb/IIIa Blockade Study Group) Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
21. CAPTURE (C7E3 Fab AntiPlatelet Therapy in Unstable Refractory angina) Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349: 1429-35.
22. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR Jr, Schwartz RS, Mousa SA. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res 1997; 36: 408-28.
23. Shappell SB, Toman C, Anderson DC, Taylor AA, Entman ML, Smith CW. Mac-1 (CD11b/CD8) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 1990; 144: 2702-11.
24. Simon DI, XU H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Thromb Vasc Biol 1997; 17: 528-35.
25. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, Smith CW. Chimeric 7E3 Fab (ReoPro) decreases detectable CD IIb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 33: 97-106.
26. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.
27. Kang KT, Jeong MH, Kim NH, Rhew JY, Lee SH, Park JC, Lee SU, Kim KH, Choi MJ, Ahn YK, Cho JG, Choi WJ, Cho DL, Park JT, Kang JC. The inhibitory effect of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on porcine coronary stent restenosis. Korean J Med 2001; 60: 314-23.
28. Park OY, Jeong MH, Kim JH, Kim W, Lee SH, Hong YJ, Kim JH, Park WS, Kim IS, Choi MJ, Ahn YK, Park JT, Cho JG, Park JC, Cho DL, Kang JC. The inhibitory effects of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on neointima formation and inflammatory response in porcine coronary stent restenosis. Korean Circ J 2003; 33: 439-45.
29. Hong YJ, Jeong MH, Kim W, Lim SY, Hong SN, Lee SH, Kim KH, Yun KH, Kang DG, Lee YS, Park HW, Kim JH, Ahn Y, Cho JG, Park JT, Park CS, Park JC, Kang JC. The effects of abciximab (ReoPro(r))-coated stents on extracellular matrix synthesis and apoptosis. Korean Circ J 2005; 35: 290-301.
30. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-74.
31. Salame MY, Verheye S, Crocker IR, Chronos NA, Robinson KA, King SB 3rd. Intracoronary radiation therapy. Eur Heart J 2001; 22: 629-47.
32. Faxon DP. Systemic drug therapy for restenosis: "deja vu all over again". Circulation 2002; 106: 2296-8.
33. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, Ferrero V, Chiariello L, Gioffre PA, Romeo F, Crea F; Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation Study. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40: 1935-42.
34. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 1994; 90: 2070-84.
35. Wohrle J, Al-Khayer E, Grotzinger U, Schindler C, Kochs M, Hombach V, Hoher M. Comparison of the heparin coated vs the uncoated Jostent - no influence on restenosis or clinical outcome. Eur Heart J 2001; 22: 1808-16.
36. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 2003; 107: 3003-7.
37. O'Neill WW, Leon MB. Drug-eluting stents: costs versus clinical benefit. Circulation 2003; 107: 3008-11.
38. Kereiakes DJ. Hippocrates revisited: the evidence for drug-eluting stents. Circulation 2003; 107: 3012-4.
39. Hong YJ, Jeong MH, Kim W, Lim SY, Lee SH, Hong SN, Kim JH, Ahn YK, Cho JG, Park JC, Cho DL, Kim H, Kang JC. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 2004; 94: 1050-4.
40. Kim W, Jeong MH, Kim KH, Sohn IS, Hong YJ, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Cho DL, Kang JC. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006; 47: 933-8.
41. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-50.
42. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.